HIGHLIGHTS
- What: This study has delineated a previously unappreciated mechanism by which CPS1 modulates glucagoninduced hepatic gluconeogenesis through the CaMKII/ FOXO1 signaling cascade and offered a potential natural inhibitor of CPS1, which may show therapeutic benefits in the management of glucose metabolism disorders.
- Who: Daniele Maria-Ferreira and colleagues from the Instituto de Pesquisa Pelé Pequeno Príncipe, Brazil Zunyi Medical University, China have published the research: CPS1 augments hepatic glucagon response through CaMKII/ FOXO1 pathway, in the Journal: (JOURNAL) of 24/05/2024
- Future: Investigation is necessary including the use of liver-specific . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.